MedMira (TSXV:MIR) Cyclically Adjusted PB Ratio: (As of Aug. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is MedMira Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


MedMira  (TSXV:MIR) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


MedMira Cyclically Adjusted PB Ratio Related Terms


MedMira Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for MedMira's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedMira Cyclically Adjusted PB Ratio Chart

MedMira Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MedMira Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TSXV:MIR vs VRTX, REGN, RVMD: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, MedMira's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedMira Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where MedMira's Cyclically Adjusted PB Ratio falls into.



MedMira Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

MedMira's Cyclically Adjusted Book per Share for the quarter that ended in Apr. 2026 is calculated as:

For example, MedMira's adjusted Book Value per Share data for the three months ended in Apr. 2026 was:

Adj_Book=Book Value per Share/CPI of Apr. 2026 (Change)*Current CPI (Apr. 2026)
=-0.035/132.7364*132.7364
=-0.035

Current CPI (Apr. 2026) = 132.7364.

MedMira Quarterly Data

Book Value per Share CPI Adj_Book
201607 -0.012 101.844 -0.016
201610 -0.012 102.002 -0.016
201701 -0.012 102.318 -0.016
201704 -0.013 103.029 -0.017
201707 -0.014 103.029 -0.018
201710 -0.015 103.424 -0.019
201801 -0.016 104.056 -0.020
201804 -0.017 105.320 -0.021
201807 -0.017 106.110 -0.021
201810 -0.018 105.952 -0.023
201901 -0.019 105.557 -0.024
201904 -0.020 107.453 -0.025
201907 -0.021 108.243 -0.026
201910 -0.021 107.927 -0.026
202001 -0.022 108.085 -0.027
202004 -0.023 107.216 -0.028
202007 -0.024 108.401 -0.029
202010 -0.023 108.638 -0.028
202101 -0.023 109.192 -0.028
202104 -0.024 110.851 -0.029
202107 -0.024 112.431 -0.028
202110 -0.025 113.695 -0.029
202201 -0.016 114.801 -0.018
202204 -0.017 118.357 -0.019
202207 -0.018 120.964 -0.020
202210 -0.019 121.517 -0.021
202301 -0.019 121.596 -0.021
202304 -0.020 123.571 -0.021
202307 -0.022 124.914 -0.023
202310 -0.023 125.310 -0.024
202401 -0.023 125.072 -0.024
202404 -0.024 126.890 -0.025
202407 -0.026 128.075 -0.027
202410 -0.028 127.838 -0.029
202501 -0.029 127.443 -0.030
202504 -0.031 129.102 -0.032
202507 -0.032 130.290 -0.033
202510 -0.033 130.603 -0.034
202601 -0.034 130.366 -0.035
202604 -0.035 132.736 -0.035

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


MedMira Business Description

Other Exchanges MMIRF:USA
Address 155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company engaged in the research, development, and manufacturing of rapid diagnostics and technologies. The company operates in one reportable operating segment, rapid diagnostic products and services. Its product line includes HIV, COVID-19, syphilis, Multiplex, Miriad RVF Toolkit, and H. pylori. The company generates revenue from North America, Europe, and other regions, with the majority generated from North America.